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ComplementComplement is an essential component of innate immunity and a major trigger of inﬂammatory responses. A
critical step in complement activation is the formation of the C3 convertase of the alternative pathway (AP), a
labile bimolecular complex formedby activated fragments of the C3 and factor B components that is fundamental
to provide exponential ampliﬁcation of the initial complement trigger. Regulation of the AP C3 convertase is
essential to maintain complement homeostasis in plasma and to protect host cells and tissues from damage by
complement. During the last decade, several studies have associated genetic variations in components and
regulators of theAPC3 convertasewith anumberof chronic inﬂammatorydiseases and susceptibility to infection.
The functional characterization of these protein variants has helped to decipher the critical pathogenic
mechanisms involved in some of these complement related disorders. In addition, these functional data together
with recent 3D structures of the AP C3 convertase have provided fundamental insights into the assembly,
activation and regulation of the AP C3 convertase.ológicas, Ramiro de Maeztu 9,
15360432.
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ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. The complement system
1.1. Overview
Complement is a major component of innate immunity with crucial
roles in microbial killing, apoptotic cell clearance, immune complex
handling and modulation of adaptive immune responses [1,2]. The
complement cascade is triggered by three activation pathways, the
classical pathway (CP), the lectin pathway (LP) and the alternative
pathway (AP), which converge in the central and most important step
of complement activation: the cleavage of C3 to generate the activated
fragment, C3b. The critical step in these activation pathways is the
formation of unstable protease complexes, named C3 convertases
(C3bBb in theAP; C4b2a in theCP/LP).WhenC3b is generated, a reactive
thioester is exposed which is attacked by nucleophiles (such as amine
groups) on adjacent surfaces, resulting in covalent binding of C3b to the
surface, targeting it for destruction and initiating inﬂammation. The
efﬁcacy of the complement cascade depends on the AP C3 convertase
ampliﬁcation loop in which the C3b generated by the convertase forms
more AP C3 convertase and provides exponential ampliﬁcation to the
initial activation (Fig. 1) [3].
In contrast to the CP and the LP, whose activation is triggered by
immune complexes and bacterial mannose groups, respectively, the APis intrinsically activated. Spontaneous activation of C3 in plasma occurs
through the “tick-over”mechanism,which is initiated by the generation
of a ﬂuid phase C3b-like molecule, called C3i or C3(H2O), by aqueous
hydrolysis of the internal C3 thioester [4]. Activation of C3 may also
occur by continuous low rate cleavage of C3 to C3b by plasma proteases
[5]. The balance between the rate atwhich the initial trigger is ampliﬁed
and the degree to which C3b and the AP C3 convertases are inactivated,
determines the progression of the complement cascade to cell damage
and death. Foreign substances on microbial pathogens (alternative
pathway; AP), antibodies (classical pathway; CP), or mannan (lectin
pathway; LP), tip the balance in favor of ampliﬁcation, causing target
opsonisation. The complement system includes other proteins, such as
properdin, which stabilize the AP C3 convertase and serve as a focal
point for promoting local ampliﬁcation of complement [6]. The lytic
pathway ﬁres when the AP C3 convertase incorporates one additional
C3b molecule, which creates the C5 convertase and switches substrate
speciﬁcity from C3 to C5, a C3 homologue. C5 cleavage triggers
inﬂammation through production of C5a, leukocyte recruitment and
initiation of membrane attack complex (MAC) formation. The MAC
contains C5b plus the complement components C6, C7, C8 and C9, and
lyses cells by punching holes through the membrane [7].
1.2. Complement and disease
In health, activation of C3 in the blood is kept at a low level and
deposition of C3b and further activation of complement are limited to
the surface of pathogens. Dysregulated complement activation in
Fig. 1. Complement activation and regulation.
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Complement is implicated in a long list of diseases [8], including rheu-
matoid arthritis (RA), systemic lupus erythematosus (SLE), glomerulo-
nephritis, multiple sclerosis (MS), ischaemia/reperfusion injury and
transplantation, in eachof these diseases complement acts to sustain the
‘vicious cycle’ of inﬂammation and perpetuate tissue damage. In recent
years, several reports have established that dense deposit disease (DDD)
[9–12], hemolytic uremic syndrome (HUS) [13–22] and age-related
macular degeneration (AMD) [23–32], are each associated with
mutations or polymorphisms in the components and regulators of the
AP C3 convertase (Table 1). These disorders are considered prototypic
diseases caused by complement dysregulation.Table 1
Risk factors associated with aHUS, DDD and AMD.
aHUS DDD AMD
Genetic factors
Rare mutations CFH CFH CFH
MCP C3
CFI
CFB
C3
THBD
Common
polymorphisms
CFH CFH CFH
MCP CFHR1/CFHR3 AMRS2
CFHR1/CFHR3 CFHR5 CFB
C2
C3
CFHR1/CFHR3
C1INH
TLR3
Autoantibodies Factor H C3Nef,
factor H
Environmental
factors
Infection Infection (?) Smoking
Immunosuppres. drugs Diet
Cancer therapies Exercise, etc.
Oral contraceptives Pregnancy
Childbirth, etc.1.2.1. Hemolytic uremic syndrome
HUS is a rare disease characterized by renal endothelial cell injury and
thrombosis (thrombotic microangiopathy), resulting in hemolytic anae-
mia, thrombocytopenia and renal failure. Typically, HUS follows infections
by enterohemorrhagic E. coli (EHEC) and has a relatively good prognosis.
In contrast, atypical forms of HUS (aHUS), not associated with EHEC,
affecting both adults and very young children, have a very poor long-term
prognosis with more than 90% of the cases ending in end stage renal
disease (ESRD) [33]. Recurrenceof aHUS in thegraftedkidneys is common
with amortality ratewhichapproaches30%.Mutationsorpolymorphisms
in complement genes are the main genetic risk factors contributing to
aHUS. In fact, analysis of the genes encoding the complement AP proteins
factorH (fH), factor I (fI),membrane cofactorprotein (MCP), C3 and factor
B (fB) reveals a genetic defect in at least one of these in approximately 50%
of the aHUS patients [34]. Functional characterization of many of these
mutations has established that they cause complement dysregulation
which affects primarily the protection of cellular surfaces from comple-
ment activation. When complement activation is triggered in carriers of
these aHUS-associated complement mutations, deposition and ampliﬁ-
cation of C3b on the cellular surfaces in the microvasculature cannot
be controlled, resulting in tissue damage and destruction. Importantly,
complement dysregulation may result from either a defect in the
regulatory proteins (i.e., loss-of-function or expression mutations in fH,
fI orMCP) or the AP complement components (i.e., gain-of-function in C3
or fB). In addition to rare mutations, common polymorphisms in fH andMCP are also associated with aHUS and contribute to the genetic
predisposition, either by increasing risk or conferring protection [35,36].
1.2.2. Dense deposit disease
DDD is a rare formof glomerulonephritis which affects both children
and young adults and frequently results in ESRD [37]. The morphologic
hallmark ofDDD is thepresence of dense depositswithin the glomerular
basement membrane (GBM), as resolved by electron microscopy. The
chemical composition of thedense deposits is largely unknown.Notably
IgG is absent from them and other regions of the glomerulus, which
excludes a role for immune complexes in dense deposit formation. DDD
is associated with complement abnormalities which lead to intense
deposition of C3 in GBM and persistent reduction of C3 serum levels.
Familial cases of DDD are exceptional but extremely informative. They
have revealed mutations in fH and C3 associated with DDD which
demonstrated that control of complement activation is impaired inDDD
patients. As with aHUS, dysregulation of the complement system may
result from loss of activity of the complement regulatory protein fH or
may also be a consequence of mutations that increase the activity of the
AP C3 convertase. The functional characterization of human DDD-
associated fH and C3 mutations [11,38] and previous studies in animal
models [39–41] have provided conclusive evidence that ﬂuid phase
complement dysregulation, resulting in the continuous generation of
C3b in plasma, plays a major role in DDD pathogenesis.
1.2.3. Age-related macular degeneration
AMD is the most common cause of visual disability in the elderly in
developed countries. The hallmark of early-stage disease is the
development of drusen, lipoproteinaceous deposits localized between
the retinal pigment epithelium (RPE) and Bruch's membrane. Later, an
extensive atrophy of the RPE and overlaying photoreceptor cells
(geographic atrophy, GA) or aberrant choroidal angiogenesis is
observed. This choroidal neovascularization (CNV) under the macular
area is the leading cause for blindness. Although the pathogenesis
of AMD is still unclear, it has been proposed that the inﬂammatory
response plays an important role in its development [42]. The con-
tribution of genetics to the development of AMD is considerable,
representing as much as of 70% of the total predisposing factors. Two
major AMD susceptibility loci (1q31, CFH, and 10q26, LOC387715/
HTRA1) which independently contribute to AMD disease risk have been
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association analyses [23,26,27,29,43]. The ﬁrst of these susceptibility
loci is in the coding region of the ﬂuid phase complement control
protein, fH, implicating complement in disease etiology. Indeed, these
initial ﬁndings have been followed by a number of reports establishing
additional genetic associations between a number of common poly-
morphisms in other complement genes and AMD [24,25,28,30–32].
Interestingly, many of these complement polymorphisms are also
associated with aHUS and DDD, demonstrating that complement
dysregulation is a common link between these pathologies. However,
in contrast to aHUS and DDD, the precise functional alterations in
complement which lead to AMD remain unclear.
In the following sections, we will describe how the functional
characterization of the complement genetic variations associated with
disease has provided insights into the underlying pathogenic mechan-
isms of disease. Importantly, these data also provide important insights
into structural aspects of assembly and regulation of the AP C3
convertase.
2. The AP C3 convertase
2.1. The components of the AP C3 convertase
The generation of the AP C3 convertase begins in vivo with the
interaction between C3b (or the C3b-like molecule C3(H2O)) and fB,
in a Mg2+-dependent manner, to form the proconvertase C3bB (or C3
(H2O)B). In the presence of factor D (fD), fB is cleaved and the N-
terminal Ba fragment is released from the C3bB complex, resulting in
the active AP C3 convertase, C3bBb (or C3(H2O)Bb).
C3 is a large protein of 190 kDa composed of two polypeptides
chains of 115 and 75 kDa, respectively. The crystal structure of nativeFig. 2. Three-dimensional structure and domain organization of fB, C3 and C3b. Left panels
panels show different views of the three-dimensional structures of fB, C3 and C3b. In all pa
Milder et al. [59] (PDB ID 2OK5), C3 was obtained from Janssen et al. [44] (PDB ID 2A73) a
composition between C3 and C3b is the ANA domain that is cleaved when C3 is activated to
resolution of 2.5 nm to highlight the overall “low-resolution” structural organization of them
is composed of the Bb fragment comprising the serine-protease (SP) and von Willebrand fa
SCR3. C3 is composed of a ring comprising 8 macroglobulin domains (MG ring), crowned by
after the ANA domain is released during C3 activation.C3 has been resolved at atomic resolution using X-ray crystallography
[44], and reveals an intricate arrangement of 13 domains, including an
anaphylatoxin domain (ANA; C3a), a small link (LNK) domain, a core
of eight homologous macroglobulin domains (MG1–8) forming a ring
(MG ring), a CUB domain connecting this ring with a TED domain that
contains the reactive thioester, and the C345C domain (Fig. 2). As
indicated previously, the reactive thioester is shielded in native C3 so
that it is not accessible. Activation of C3 into C3b (or C3(H2O)) induces
a huge conformational displacement of the TED domain exposing the
reactive group to nucleophilic reagents such as hydroxyl or amine
groups [45–47]. Release of C3a (ANA domain) from the alpha chain of
C3 generates a novel C3 domain termed α′NT.
The α′NT and C345C domains in C3b include binding sites for fB
required for the AP C3 convertase formation [48–50]. These domains
are located in a part of the C3 molecule which undergoes large rear-
rangement upon activation of C3 into C3b [45], which explains why C3
does not interact with fB. Similarly, structural analyses have suggested
that formation of the AP C3 convertase probably depends on the
structure and orientation of the CUB domain of C3b and that the
interaction between C3b and fB is independent of the TEDdomain [51].
fB (90 kDa) circulates as an inactive pro-enzyme in plasma. It is
composed of ﬁve structural domains. The Ba fragment at the N-
terminus comprised three short consensus repeats (SCRs), whereas
the large Bb fragment at the C-terminus comprised a von Will-
ebrand type A (VWA) domain followed by a serine-protease (SP)
domain (Fig. 2). Mutagenesis analyses of fB have revealed a number
of residues near the Mg2+-dependent metal ion-dependent adhe-
sion site (MIDAS) and in the α1 helix in the VWA domain of the Bb
fragment which mediate the initial recognition of C3b by fB [52–54].
This initial interaction also involves contacts between C3b and the
SCR1–3 domain (Ba propeptide segment) [55–58].outline the domain organization of fB and C3 in their primary structure whereas right
nels each domain has been colored differently. The structure of fB was obtained from
nd C3b was obtained from Janssen et al. [45] (PDB ID 2I07). The difference in domain
C3b. For representation, atomic structures of fB, C3 and C3b were low-pass ﬁltered to a
olecules and the large-scale conformational changes taken place during C3 activation. fB
ctor type A domain (VWA), packed against the Ba segment containing SCR1, SCR2 and
the C345C domain, as well as CUB and TED domains that undergo a large displacement
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The crystal structure of human fB, recently resolved at 2.3 Å
resolution, demonstrated that the Ba domain is not extended but
folded back onto the Bb domain (Fig. 2) [59]. These structural data
also indicated that the ﬁrst SCR likely hinders access of the ligand
C3b to the MIDAS of the VWA domain and that the triad of SCR
domains is probably only weakly associated with the VWA and SP
domains. Most interestingly, comparison of the fB pro-enzyme [59]
and the Bb fragment [60] structures, led to the suggestion that fB
must undergo conformational changes upon binding to C3b, so
that the long linker domain between SCR3 and the VWA domains
of fB, which contains the scissile bond, becomes accessible to fD
[59,60].
Very recently, better insight into the mechanisms leading to C3
convertase assembly and activation have been obtained thanks to the
combination of high resolution studies by X-ray crystallography and
medium resolution electron microscopy (EM) studies [59,61–64].
These analyses have shown that fB binds to C3b in the closed
conformation of the pro-enzyme through interactions involving both
the VWA and the SCR domains (Fig. 3). The VWA domain binds C345C
whereas residues located in the SCR1–3 domain contact the α′NT
region, MG2, MG3, MG7 and CUB domains. The SP domain does not
contact C3b. After this initial loading, a large conformational change
occurs in fB, opening its structure and generating an “activated”
conformation where the scissile site is likely accessible to fD (Fig. 3).
Upon cleavage by fD and release of the Ba fragment, the active AP C3
convertase C3bBb is maintained by interactions between the C345C
and VWA domains of C3b and Bb, respectively. The Bb fragment
projects outwards from the complex so that the SP domain is far from
contacting C3b [59,61,63]. Additionally, the EM structure of the C3
convertase suggests that some conformational ﬂexibility of the
C345C-VWA-SP arrangement permits the accommodation of the C3
convertase to the substrate so that the SP domain can reach and cleave
C3 [63] (Fig. 5B).Fig. 3. Assembly and activation of the AP C3 convertase. The ﬁgure describes the sequence o
described in the text. C3 is an inactive protein not capable of interacting with fB. Activation o
TED domain and the exposure of new surfaces that are now competent for fB recognition.
conformational change that leads to an open conformation of fB likely exposing the factor D
Cleavage by fD removes the Ba fragment to generate an active AP C3 convertase with th
conformation of the AP C3 proconvertase and the AP C3 convertase have been obtained after
ID 2A73), C3b (Janssen et al.[45]; PDB ID 2I07), the C3 convertase (Rooijakkers et al. [61]; P
[64]; PDB ID 3HRZ, Torreira et al., [62] and Torreira et al., [63]. Themodel for the open conform
resolution obtained using electron microscopy (EMD ID EMD-1583, Torreira et al., [62]). The
model for the open conformation of fB bound to C3b has been proposed based on the ﬁtting
location of the fB domains in the open conformation of the AP C3 proconvertase waits for a2.3. Disease-associated mutations and polymorphisms in the AP C3
convertase components
Factor B mutations are characteristic of a subgroup of aHUS patients
showing persistent activation of the AP [16,65]. Four of thesemutations,
D279G, F286L, K323E and K350N (all amino acids are numbered from
the initial Met), have been functionally characterized and are gain-of-
function mutations that result in enhanced formation of the C3bBb
convertase or increased resistance to inactivation by complement
regulators [16,65] (Fig. 4). Proconvertase (C3bB) formation by mutant
fB-286L is much enhanced, producing more active enzyme in vivo than
the normal fB-286F allele. In contrast, generation and natural decay of
the AP C3 convertase formed by fB-323E is normal; however, it is more
resistant to accelerateddecayby the complement regulatorsDAFand fH,
which also results in enzyme dysregulation and increased C3-cleaving
activity in vivo. fB-279G and fB-350N increase enormously the afﬁnity
between fB and C3b, which results in both enhanced enzyme formation
and the generation of a AP C3 covertase which is very stable [16,65] and
resistant to accelerateddecay by the complement regulators DAF and fH
[16] (Fig. 4).
The location of the D279G, F286L and K350Nmutations in the VWA
domain of the Bb fragment, close to the MIDAS site at the VWA-C345C
interface provides a simple explanation for the functional consequences
of these gain-of-function mutations [16,65]. In contrast, the K323E
mutation ismore difﬁcult to explain. It is located in the VWAdomain, on
the opposite side to the α1 helix and far away from the MIDAS site
which mediates the initial recognition of C3b by fB, this explains why
thismutationdoesnot affect formation and spontaneousdecayof theAP
C3 convertase. A recent description of another aHUS-associated fB
mutation, also altering the 323K amino acid residue (K323Q) [66],
further supports that this residue of fB deﬁnes a critical site for the
accelerated decay of the AP convertase by DAF and fH (Fig. 4). Point
mutagenesis studies of fB conﬁrm that this region of Bb, distal to the
MIDAS site, inﬂuences binding of DAF lending support to the hypothesis
that this region is critical for efﬁcient accelerated decay [67].f events that take place during the assembly and activation of the AP C3 convertase as
f C3 to C3b induces a large conformational change including a large displacement of the
fB initially binds to C3b in a closed conformation. Subsequently, fB undergoes a large
(fD) cleavage site between the SCR1–3 (Ba propeptide segment) and VWA domains.
e serine-protease (SP) domain projecting outwards. Models for C3, C3b, the closed
low-pass ﬁltering of the atomic coordinates of C3 (obtained from Janssen et al. [44]; PDB
DB ID 2WIN), and the conformation of the C3 proconvertase described by Janssen et al.
ation of the AP C3 proconvertase shows the experimental 3D reconstruction atmedium
density corresponding to C3b is colored in orange and that of fB in gray. A hypothetical
of atomic structures into the medium resolution EM density [62], However, the precise
n experimental structure at high resolution.
Fig. 4. Disease-associated mutations in fB. A) For simplicity only two representative
aHUS-associated fB mutations, D279G and K323E are identiﬁed within the three-
dimensional structure of the C3 convertase (Rooijakkers et al. [61]; PDB ID 2WIN). The
magnesium ion in the MIDAS site of the VWA domain has been represented as a yellow
dot. The D279G mutation (red) is at the interface between the VWA and the C345C
domains, whereas the K323E fBmutation (orange) is located on top of the VWA domain
of Bb, away from the MIDAS site and the site of interaction between the Bb and C3b. B)
Surface plasmon resonance (Biacore) analysis of the D279G and K323EfB mutations.
The functional effects of the D279G and K323E mutations, located on opposing sides of
the MIDAS site, were investigated by ﬂowing recombinant (r) fB and native fD over a
C3b-coated chip to form convertase. Formation of C3bBb-323E convertase (orange line)
was normal and the enzyme decayed with a half-life of 319 s, comparable to that
formed by wild type rfB (black line). However, whereas the wild type convertase was
rapidly and completely dissociated by soluble DAF, the fB-323E mutant convertase
demonstrated resistance to accelerated decay. The C3bBb-279G convertase (red line)
was formed at abnormally high levels, likely due to high afﬁnity interaction, and was
very stable. Similarly to the fB-323E mutant convertase, the enzyme was highly
resistant to accelerated decay.
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gain-of-function mutations, causing profound complement dysregula-
tion in plasma, exclusively associate with aHUS and not with DDD or
AMD. Perhaps this apparent aHUS speciﬁcity, and the incomplete
penetrance of the disease that is also observed among fB mutation
carriers, illustrate the need of a second hit to manifest the potential
pathogenecity of the fBmutations. For example, increased complement
activation caused by gain-of-function mutations in fB or by infection,
may also require impaired surface protection to trigger aHUS. In this
respect, it is interesting that all aHUS patients with fB mutations in our
cohort were also carriers of a common polymorphism in theMCP gene
(the MCPggaac allele) associated with decreased expression and
increased risk of developing aHUS [16,36].
Two common polymorphisms in the N-terminal region of fB, L9H and
R32Q, strongly associatewithprotection toAMD[25]. L9H is located in the
signal peptide and was suggested to modulate secretion of fB. The R32Q
variation reduces the haemolytic activity of fB by decreasing the
interaction between the Ba fragment and C3b [68]. These data provide
an explanation for the association; the observed protection in each casewasascribed toa reducedactivityof the complementalternativepathway.
In addition these analyses illustrate that the 8-aa long unstructured
fragment at the amino terminus of the Ba fragment plays an important
role in the initial interaction between fB and C3b. Similarly it has been
reported that the C3 polymorphism, R102G, increases risk to AMD [32].
Our preliminary data suggest that this association is a consequence of
increased AP activity of the C3-102G variant compared to the C3-102R
(our unpublished results).
Mutations in C3 are associated with aHUS [15,66,69] and DDD [38].
Different experimental approacheshave shown that thesemutations alter
the sensitivity of C3b to inactivation by fH and MCP, and change the
resistance of the AP C3 convertase to accelerated decay by fH and DAF
[15,38,65, ourunpublished results]. Importantly, theseC3mutations seem
to affect differentially the sensitivity to regulation by fH and the
membrane associated regulators DAF and MCP. Thus, whilst the C3
mutation associated with DDD affects only regulation by fH [38], the
aHUS-associated C3 mutations affect primarily the cell surface regulation
[38,65, our unpublished results], further supporting the hypothesis that
the site of complement dysregulation (surface vs ﬂuid phase) is critical in
the pathogenesis of aHUS and DDD. The differential effects of the C3
mutations on fH, DAF and MCP regulatory activities illustrate the
complexity of the interactions between C3b and the complement
regulators. We discuss below the data generated from the functional
characterization of these disease-associated C3 mutations which also
suggest that regulation by fH, DAF or MCP has distinct structural
requirements in C3b.2.4. Substrate recognition by the AP C3 convertase
Understanding how the AP C3 convertase recognizes its substrate
has been a challenge for many years. Both novel structural data and
disease-associated C3 mutations are now providing important insights
into the regions of C3 and C3b relevant to substrate recognition by the
AP C3 convertase [38,65,70].
Dimeric complexes of the AP C3 convertase (C3bBb) were
observed in the crystals stabilized with the staphylococcal inhibitor,
SCIN, strongly suggesting that the interface between the two C3b
monomers in the crystal represented the natural binding interface
between C3 and C3bmolecules during C3 substrate recognition by the
AP C3 convertase [61]. This binding interface is a large surface that
involves an area of C3 (or C3b) including the domains MG3, MG4–5
and MG6–8 (Fig. 5). The contribution of these C3 regions to substrate
recognition is further supported by the fact that the binding sites for
the inhibitors compstatin [71], CRIg [47] and antibody S77 [72], all of
which block substrate binding to the AP C3 convertase, map within
this area.
Very recently, a remarkable C3 mutation associated with DDD has
been shown to render C3 resistant to cleavage by the AP C3 convertase
[38]. The mutation is a deletion of two amino acids (Asp923, Gly924;
923delDG) in the MG7 domain of C3 that does not alter the normal
expression and overall structure of C3 (Fig. 5A). A deletion of two
amino acids, however, will displace amino acid residues on either side
from their positions in the wild type protein structure. N-terminal of
the deletion is a surface-exposed loop (residues Val916 to Ser922)
located within the postulated region of interaction between C3 and
C3b molecules during C3 substrate recognition by the AP C3
convertase (Fig. 5). Based on these structural data and the functional
data generated from the 923delDG C3 mutant we suggest that this
particular loop N-terminal of the 923delDG mutation is an important
interaction site between C3 and C3b. The mutation data indeed
suggest that C3 and C3b contact at this region and that it is the
presence of the SCIN inhibitor that separates them in the crystal
structure (Fig. 5C). This region in the surface of the MG7 domain may
represent a novel and important therapeutic target for inhibition of C3
activation.
Fig. 5.Model for the substrate C3 recognition by theAPC3 convertase. A) Themediumresolution three-dimensional structure of thepuriﬁedC3-923delDGmutant determinedby electron
microscopy (EM) illustrates that this C3mutant, despite being resistant to cleavage by theAP C3 convertase, shows nomajor structural changes compared to normal C3 [38]. The structure
is represented as a gray transparent density with the atomic structure of wild type C3 (Janssen et al. [44]; PDB ID 2A73) integrated within it. The position of the 923delDG C3mutation is
indicated with a circle. Note that upstream of the mutation there is a peptide loop exposed on the adjacent surface in the wild type MG7 domain of C3 (right panel) which will likely be
modiﬁed by the 923delDG mutation. B) The atomic structure of the C3 convertase stabilized with the bacterial inhibitor SCIN, revealed a dimeric interface between two C3b molecules
contacting eachother through theMGrings. This promptedGros and collaborators to suggest that a similar interaction could take place during the recognition of the C3 substrate by theAP
C3 convertase. Theﬁgure shows amodel of such a putative complex based on their atomic structures (Rooijakkers et al [61]; PDB ID 2WIN). In thismodel, the contact between the twoMG
rings is sustainedby interactionsat thebottomof theMGring, locating theSPdomainclose to its target sequence inC3. Theﬁgure illustrates that the923delDGmutation is locatedat the top
of the MG ring, which suggests that this region is also relevant for the formation of the complex between C3 and the AP C3 convertase. Since the 923delDG mutation completely blocks
cleavage by the convertase, we speculate that the presence of the SCIN inhibitor in the crystal structure of the C3 convertase (Rooijakkers et al. [61]; PDB ID 2WIN) may prevent contact
between theMG rings at the site of the923delDGmutationwhichwould otherwise bepresent in the active complex. Themodel also reveals that there is a substantial distance between the
SPdomainof theAP convertase and theC3 substrate.However, the structure of theAPC3 convertase in solutionobtained byelectronmicroscopy [62], revealed that theBb fragment,which
project outwards, displays considerable conformational ﬂexibility, which is probably important for the SP domain to reach its target sequence.
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3.1. The regulators of the AP C3 convertase
Following cleavage of C3 to nascent C3b, nucleophilic attack on the
internal thioester bond results in covalent binding of C3b to the
activating surface, thus focusing further activation on the target cell
(Fig. 1). Complement is a double-edged sword because nascent C3b
can bind not only to pathogens, but also to “innocent” adjacent host
cells, initiating inappropriate foci of complement activation. To
prevent damage to self and to avoid wasteful consumption of
components, complement is under the control of multiple regulatory
proteins which limit complement activation, either by inactivating
C3b or by dissociating the AP C3/C5 convertases (Figs. 1 and 6).
Foreign surfaces, such as those of pathogens, are usually devoid of
membrane regulatory proteins, which inactivate the AP C3 conver-
tase. This lack of regulation thus leads to ampliﬁcation of complement.
fH (155 kDa) is a single polypeptide composed of 20 SCRs arranged
in a contiguous fashion. fH is the prototypic AP regulator, essential in
order to maintain complement homeostasis and to restrict the action
of complement to activating/pathogen surfaces. fH binds to C3b,
competing with fB for binding to C3b in proconvertase formation and
accelerating the decay of the AP C3/C5 convertase enzymes. It also acts
as a cofactor for the factor I-mediated proteolytic inactivation of C3b.fH regulates complement both in the ﬂuid phase and on cellular
surfaces. However, whilst fH binds and inactivates C3b promptly in
the ﬂuid phase, the inactivation of surface-bound C3b by fH is
dependent on the chemical composition of the surface to which C3b is
bound. The fH molecule includes different interaction sites for C3b
and polyanions, which delineate distinct functional domains at the N
and C-termini. The C3b binding site in SCR1–4 is the only site essential
for the decay and factor I cofactor activities of fH. Similarly, the C3b/
polyanion-binding site located within SCR19–20 is the most impor-
tant site for preventing alternative pathway activation on host cells. In
the presence of polyanions, such as sialic acids, glycosaminoglycans or
sulphated polysaccharides (heparins), the afﬁnity of fH for surface-
bound C3b increases as a consequence of the simultaneous recogni-
tion of both polyanionic molecules and surface-bound C3b by the
same fH molecule (Figs. 6 and 7) [73].
On cell membranes the complement regulators MCP and DAF
inhibit the C3/C5 convertase enzymes. DAF accelerates decay of the
convertases, whereas MCP binds to C3b on the surface and acts as a
cofactor for its irreversible proteolytic inactivation by the plasma
protease factor I. Both DAF and MCP are composed of four SCR at the
amino terminus followed by a short ‘stalk’ which is heavily
glycosylated and either a glycosyl phosphatidyl inositol (GPI) anchor
(DAF) or a transmembrane domain and cytoplasmic tail with
signaling properties (MCP) (Fig. 6) [74].
Fig. 6. Activation and regulation of the complement AP in plasma and on cellular surfaces. Cartoon illustrating the role of fH, fI, MCP and DAF in the regulation of the AP of complement in
plasma and on the surface of endothelial cells or pathogens. This illustrates the crucial role of the interaction between the C-terminal region of fH and negatively charged heparins or
glycosaminoglycans (GAGs) on endothelial cells which discriminates between self cells and pathogens, devoid of these negatively charged components. When heparins and GAGs are
present, the avidity of fH for C3b depositedon cell surfaces increases and fHefﬁciently controls ampliﬁcationof theAPanddamage to self-tissues, both bydissociating theAPC3 convertase
and inactivating C3b. On surfaces lacking negatively charged molecules, like pathogens, there is no interaction through the C-terminal region of fH, which decreases binding avidity and
allows ampliﬁcation of C3b deposition, triggering opsonophagocytosis and cell lysis. Mutations that disrupt the function of the C-terminus of fH, like those associatedwith aHUS, interfere
with the capacity of fH to protect self components from complement-mediated damage. Note the similarities in the functional activities between fH and the membrane associated
regulators, MCP and DAF. These proteins work together with fI to prevent damage to self and to avoid wasteful consumption of complement components.
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The crystal structure of the complex between C3b and a truncated
form of fH has shown that the ﬁrst four SCRs of fH, responsible for its
decay accelerating and factor I cofactor activities, bind C3b in an
extended conﬁguration [70]. This results in an elongated contact
interface with multiple domains of C3b, which partially overlaps that
involved in the interaction with fB in the initial steps of the AP
convertase assembly. These structural data support previous mutagen-
esis experiments and functional analyses of disease-associated muta-
tions which indicate that fH competes with fB in the formation of the
C3bB proconvertase and may interfere with the positioning of the Bb
fragment, destabilizing the active AP C3 convertase (C3bBb) [70].
Accordingly, it has been suggested that binding of fH SCR1–2 to C3b is
sufﬁcient for fH to displace Bb and account for the decay accelerating
activity of this regulator [70]. Although binding of fH to Bb is postulated
not necessary for the decay accelerating activity of fH, some degree of
interaction between fH and Bb may help to explain why the aHUS-
associated mutation altering the K323 residue in the VWA speciﬁcally
alters the decay accelerating activity of fH and not the formation or the
spontaneous decay of the AP C3 convertase [16].
Based on the conserved location of functional residues in the
homologous SCR domains of fH and DAF, it has been suggested that
similar displacement effects also play a role in the case of the decay
accelerating activity of DAF [70]. However, it has beenpreviously shown
thatwhilst DAF-SCR2 interacts with Bb, DAF-SCR4 interacts with C3b in
the C3bBb complex and alone can mediate accelerated decay [75].
Furthermore, mutagenesis data indicate that DAF and fH have non-
identical structural requirements for their decay activity [67], support-
ing two different mechanisms for the dissociation of the AP convertase.
This is also supported by the DDD-associated C3 923delDG mutation
described below [38], where deletion of two amino acids in the MG7
domain of C3b alters decay by fH, but not by DAF.3.3. Cofactor activity of fH and MCP for the fI-mediated inactivation
of C3b
fH and MCP are necessary cofactors for factor I, enabling cleavage of
C3b in the CUB domain, yielding the inactive iC3b species. The crystal
structure of the C3b-fH SCR1–4 complex revealed that fH SCR2–3 bound
to C3b adjacent to the CUB domain where the fI cleavage sites are
located [70]. fH SCR1–3 exhibits several conserved and charged patches
on its surfacewhichmaybe involved in thebindingof fI. These andother
data suggest that fI binds the C3b:fH complex at the area formed by
SCR1–3 of fH, and C345C and CUB of C3b. The current model states that
besides providing a platform for fI binding, fHmay have a second role in
cofactor activity, maintaining the position of TED whilst the connecting
CUB domain undergoes cleavage. This suggested function is supported
by disease-related mutations in either fH or TED of C3b, which indicate
an important interaction of complement regulatorswith TED [15,65,69].
As with fH and DAF, which have different structural requirements for
decay accelerating activity, analysis of theDDD-associated 923delDG C3
mutant suggests that fH and MCP, despite their common evolutionary
origins, also have different structural requirements for their cofactor
activity in the fI-mediated inactivation of C3b [38]. MCP can act as a
cofactor for fI inactivation of 923delDG in the ﬂuid phase, but fH cannot.
3.4. Disease-associated mutations and polymorphisms in complement
regulatory proteins
Missense mutations in the C-terminal region of fH are the most
prevalent genetic alterations among aHUS patients. In contrast to fH
mutations associated with DDD, fH mutations associated with aHUS
rarely result in hypocomplementemia or decreased fH plasma levels.
Most aHUS-associated fH mutant proteins express normally and have
normal cofactor activity for the factor I-mediated proteolytic inactiva-
tion of C3b in plasma [19,76]. As indicated, aHUS-associated fH
Fig. 7.Disease-associatedmutations in fH. Figure depicts the structure of fH indicating the distinct functional domains and sites of interaction with other molecules (top). The bottom
diagram illustrates the differential distribution of aHUS- and DDD-associated mutations found in factor H.
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critical for control of complement activation on cell surfaces by binding
both polyanions and deposited C3b (Fig. 7). aHUS carriers of carboxy-
terminal fH mutations express fH which has normal regulatory activity
in plasma, but a limited capacity to protect cells from complement lysis
due to a lack of binding avidity [76–78]. These ﬁndings ﬁt well with the
identiﬁcation of aHUS-associated loss-of-function mutations in MCP
and fI; mutations in both these proteins also lead to decreased
protection of host cells from complement lysis without signiﬁcantly
affecting complement homeostasis in plasma [79] (Fig. 6). The
combination of an active complement system in plasma and defective
protection of cellular membranes illustrates that aHUS is a disease
caused by uncontrolled activation of complement on cell surfaces and
damage to self. The same consequence is brought about by mutations
which decrease concentrations of fH or fI in plasma, or MCP density on
cell surfaces. In these cases, deposition and ampliﬁcation of C3b on cells
in the microvasculature cannot be controlled and tissue damage and
destruction ensues. This is clearly distinct from insufﬁcient control of
complement in plasma, which leads to complete C3 consumption and
severe hypocomplementemia characteristic of DDD patients carrying
either fH deﬁciencies [37] or fH missense mutations which knock-out
the fI-cofactor and decay accelerating activities (fH-del224K mutation)
[11]. It is most revealing that this distinction between surface and ﬂuid
phase regulation, illustrated by mutations in fH which cause different
kinds of pathology, is also a characteristic of mutations in C3. Functional
characterization of the C3 923delDG mutation associated with DDD
reveals that the convertase is resistant to the decay and cofactor
activities of fH in the ﬂuid phase, but can be regulated by themembrane
associated regulators DAF andMCP [38]. In this case, insufﬁcient control
in plasma, in the face of adequate control on cell surfaces, leads to DDD.
In contrast, C3 mutant proteins associated with aHUS were resistant to
inactivation by both fH and MCP [15, our unpublished results].
Association of mutations in complement proteins with pathology is
understandable. It is more surprising that common polymorphisms in
complement proteins are also linked to disease. The most studied
polymorphism at the CFH locus is rs1061170 which causes a Tyr402Hisamino acid substitution in fH. Several independent studies have shown
that the allele 402His confers a signiﬁcantly increased risk to AMD in
manydifferentpopulations,withanodds ratio (OR)between2.1 and7.4
[23,26,27,29]. Interestingly, the frequency of the 402His allele varies
greatly between populations, which may contribute to the observed
differences in the incidence of AMD among different ethnic groups [80].
The Tyr402His polymorphism lies in SCR7 of fH, within the cluster of
positively charged amino acids implicated in the binding of heparin, and
C3b (Fig. 7). The substitution occurs towards the centre of this module
and structural analyses of short, recombinant constructs containing this
region indicate that whilst the presence of either 402His or 402Tyr has
little effect on overall conformation, the substitutionmay affect binding
to polyanions [81]. In vitro functional studies with fH recombinant
fragments conﬁrm that the substitution of Tyr for His at position 402
alters the binding speciﬁcity of SCR7 for different glycosaminoglycans
[82,83] and decreases its binding to retinal pigment epithelial cells [84],
although the physiological relevance of these observations is still
unclear. It has also been reported that the Tyr402His polymorphism
inﬂuences the binding of fH to C-reactive protein [84–86], but the
difﬁculties in replicating these data cast doubt on their signiﬁcance [87].
The common fH polymorphism Val62Ile has been associated with
lower risk for aHUS, AMD and DDD [26,88]. Val62Ile lies within the N-
terminal region that is essential for fH regulatory activities. Consistent
with the role of complement dysregulation in these pathologies, it has
been shown that the substitution of Val for Ile at position 62 increases
the complement regulatory function of fH, thereby reducing AP
activation [89]. This is the result of an increase in the afﬁnity for fH
Ile62 for C3b, leading to more effective competition with fB for C3b
binding in proconvertase formation and enhanced cofactor activity for
the factor I-mediated inactivation of C3b. Importantly, the Val62Ile
substitution affects binding to C3b but not decay accelerating activity
suggesting that different regions in fH are involved in binding C3b/
cofactor activity and in decay accelerating activity [89].
fH Ile62 most likely protects from disease caused by complement
dysregulation because it performs better as a complement regulator than
fH Val62. One important conclusion from the functional characterization
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polymorphism described earlier, is that whilst the functional alterations
caused by these amino acid substitutions are subtle, the very nature of the
complement system will amplify these small effects. Most importantly,
these subtle effects are additive. Indeed, it has been shown that particular
combinations of these fHand fBpolymorphisms result in verydifferentAP
characteristics, markedly affecting formation and regulation of the AP C3
convertase in plasma and on cell surfaces [89]. We anticipate that
identiﬁcation of individuals carrying combinations of polymorphisms
(‘complotypes’) in complement components and regulators, which result
in high or low AP activity, will be of great importance for prediction of
disease risk and may also help in diagnosis and choice of treatment for
diseases involving complement dysregulation.
4. Concluding remarks
We have summarized our current understanding of the formation,
activation and regulation of the AP C3 convertase and have reviewed
how the analysis of genetic variants associated with different diseases
has helped to determine the molecular events which are critical in the
pathogenesis of variousdisorders. A clear conclusion fromthese analyses
is that, despite a common link involving complement dysregulation,
there are distinct functional alterations caused by these small changes in
complement proteins which are essential in disease pathogenesis. It is
nowwell established thatmutationsor polymorphismsaltering the C3b/
polyanion-binding site located at the C-terminal region of factor H, or
that decrease the levels of fI or MCP, are strongly associated with aHUS
because they speciﬁcally impair the capacity to protect host cell
membranes from complement activation. Consistent with this idea
that aHUS results from insufﬁcient protection of the host cellular
surfaces, aHUS-associated C3mutants generate activated C3bmolecules
and AP C3 convertase enzymes which are more resistant to inactivation
by surface-associated regulators. Gain-of-function fB mutations collab-
orate with additional risk factors in MCP, focusing damage by enhanced
complement activity on to cell surfaces. On the other hand, mutations
which disrupt regulatory activities in plasma cause failure of ﬂuid phase
complement control, resulting in massive activation of C3 which causes
DDD.
AMD strongly and speciﬁcally associates with a common extended
CFH haplotype carrying the 402His polymorphism, but the molecular
bases of this association are controversial and still unclear. However,
functional characterization of other common polymorphisms in compo-
nents and regulators of the AP pathway has been more rewarding,
demonstrating important differences in complement activities for
some combinations, which may have a signiﬁcant role in determining
individual predisposition to a number of common disorders. In
particular, understanding how subtle alterations, which speciﬁcally
associatewith lower risk to disease, such as those in fB and fH,may guide
future developments in complement therapeutics.
Recent advances in structure–function analyses of complement
proteins by crystallography, electron microscopy and surface plasmon
resonance have permitted a deeper understanding of the mechanistic
basis of disease-associated genetic variations. In turn, the functional
analysis of these genetic variations has aided our understanding of the
signiﬁcance of the structures and interactions solved.We anticipate that
amultidisciplinary approach involving genetics, functional analyses and
structural determination will be instrumental in achieving a complete
understanding of the assembly, activation and regulation of the AP C3
convertase. This knowledge will have important implications in
therapeutic development.
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